MAGNESIUM SULPHATE FOR ECLAMPSIA OR ECLAMPSIA PROPHYLAXIS

This LOP is developed to guide clinical practice at the Royal Hospital for Women. Individual patient circumstances may mean that practice diverges from this LOP.

Note: The additional LOP: Magnesium sulphate prior to preterm birth for fetal neuroprotection is available. Do not use both policies at the same time.

1. AIM
To safely administer magnesium sulphate for eclampsia or eclampsia prophylaxis.

2. PATIENT
Patients with eclampsia
Patients who require eclampsia prophylaxis

3. STAFF
Nursing and midwifery staff
Medical officers

4. EQUIPMENT
Magnesium sulphate 4 g in 100 mL sodium chloride 0.9%

5. CLINICAL PRACTICE

DOSAGE AND ADMINISTRATION:
Prophylaxis in women with severe pre-eclampsia:

- Administer Magnesium Sulphate intravenously via either a central or peripheral line using an infusion pump.
- Intravenous line should not be used to inject any other drugs.
- Check expiry date of premix bags prior to administration.
- **Loading Dose:** Infuse 4 g Magnesium Sulphate (100 mL premixed bag) over 20 minutes via an infusion pump.
- **Maintenance Dose:** Infuse premix bag of Magnesium Sulphate at 1 g/hr (25mL/hr of the premixed bag).
- Magnesium Sulphate infusion (in most cases) should continue for at least 24 hours after commencement.
- Attached chart should be used to document blood levels and observations.
- Adjust dosage as per regular plasma Magnesium levels.
- Check Magnesium level one hour after loading dose has been commenced and then six hourly thereafter, and in the event of any signs or symptoms of toxicity.
- Do not collect blood for serum levels from the limb receiving the infusion.
- Normal therapeutic levels are 1.5-3.5mmol/L. Toxic range 4-8mmol/L.
- Increase dose by 12.5 mL/hr (0.5g/hr) if level is sub therapeutic ie <1.5 mmol/L.
- Cease infusion if level above 4.0mmol/L and contact Dr for review.
MAGNESIUM SULPHATE FOR ECLAMPSIA OR ECLAMPSIA PROPHYLAXIS cont’d

Eclampsia Management
• Control the airway.
• Control hypertension.
• Control convulsions – commence Magnesium Sulphate infusion as per protocol for prophylaxis.
• If further seizures occur after the commencement of the infusion take blood for urgent magnesium level and give a further bolus of 2 g Magnesium Sulphate over 20 minutes intravenously (50mL of the premixed bag). Follow with infusion at 1 g Magnesium Sulphate (25mL/hr of the premixed bag).
• If seizures are not controlled, Midazolam 2 mg to 5 mg as second line agent may be given.

ADVERSE EFFECTS:
Mild: Flushing of the skin (hands, face and neck), sensation of pain or warmth in arm, and nausea (common).
More Severe: Respiratory depression, loss of reflexes, muscle paralysis, blurred or double vision, slurred speech /sleepy, cardiac conduction changes, cardiac arrest.

TOXICITY:
• Clinical monitoring is the prime method of assessing for toxicity. Blood levels are complimentary to this monitoring.

Significant toxicity can be treated with 1 g Calcium Chloride or Calcium Gluconate (10 mL in 10% w/v solution) by slow intravenous injection over three minutes.

Calcium chloride vials are available in the cardiac arrest trolleys.

PRECAUTIONS:
Administration of Magnesium Sulphate may have the following additional effects:
• Lower blood pressure (secondary to vasodilation). The dose of any current antihypertensive medication may require adjustment.
• Tocolysis.
• Decrease fetal heart rate variability.
• May cause loss of reflexes prior to toxic serum levels of magnesium are reached.
• Should be used with caution in the presence of calcium antagonists or other respiratory depressants (e.g. diazepam).
• Enhance the effects of muscle relaxants.
MAGNESIUM SULPHATE FOR ECLAMPSIA OR ECLAMPSIA PROPHYLAXIS cont’d

CONTRAINDICATIONS:
Magnesium sulphate can be extremely hazardous in the following circumstances:
- Oliguria or renal failure (magnesium concentration can reach toxic levels as elimination is predominantly renal).
- Hypocalcaemic states.
- Myasthenia gravis.
- Cardiac conditions, in particular conduction problems or myocardial damage.

DRUG COMPATIBILITIES:
Aciclovir, amifostine, amikacin, ampicillin, aztreonam, bivalirudin, caspofungin, cefotaxime, cefoxitin, cephazolin, chloramphenicol, cisatracurium, dexametomidine, doripenem, esmolol, gentamicin, granisetron, heparin sodium, hydrocortison sodium succinate, labetalol, linezolid, metronidazole, milrinone, morphine sulfate, piperacillin-tazobactam (EDTA-free), potassium chloride, remifentanil, sodium nitroprusside, trimethoprim-sulfamethoxazole, vancomycin.

OBSERVATIONS: Close observation and assessment (maternal and fetal) is required for the duration of the infusion. When the patient’s condition is unstable, the frequency of the observations will need to be increased.
- Initial observations, done at ‘0’ hour include blood pressure, respiration rate, pulse, temperature and reflexes.
- Hourly blood pressure: cease infusion if blood pressure < 110/70mmHg.
- Hourly respirations: cease infusion if respiratory rate < 10 breaths per minute.
- Hourly pulse.
- Hourly tendon reflexes usually knee reflexes but upper limbs if epidural or spinal anaesthetic in place: cease infusion if unable to elicit reflexes.
- Hourly urine output: cease infusion if urine output < 30 mL per hour for three consecutive hours.
- Fetal heart rate monitoring as clinically indicated.
- Measure temperature every 4 hours.
- Check magnesium level one hour after loading dose and then six hourly thereafter.
- Check magnesium level if there are any signs or symptoms of toxicity.
- Record all observations on attached chart.

CESSATION
- Continue infusion for 24 hours following delivery or post last seizure or as per Consultant Physician or Obstetrician.

6. DOCUMENTATION
NSW Health fluid chart
Integrated clinical notes

7. EDUCATIONAL NOTES
- Eclampsia is defined as the occurrence of de-novo convulsions in pregnancy. Incidence: 1:2000 women in developed countries.
- Magnesium sulphate acts at the cellular level competing with calcium for entry into the cell at time of depolarization, therefore possibly reducing the excitability of cells and vasospasm of vessels. Its mode of action in eclampsia and pre-eclampsia is poorly understood.
- Magnesium sulphate is excreted by the kidneys; therefore the therapeutic level will depend on the woman’s renal function.
- The recent Magpie Trail demonstrated that magnesium sulphate compared to a placebo reduced the risk of fitting by half, among 10,000 women in 33 countries worldwide.
MAGNESIUM SULPHATE FOR ECLAMPSIA OR ECLAMPSIA PROPHYLAXIS
cont’d

8. RELATED POLICIES/PROCEDURES
• Hypertension – Management in Pregnancy
• Hypertension - (severe and/or urgent) in Pregnancy guideline
• Eclampsia- management of
• Magnesium sulphate prior to preterm birth for fetal neuroprotection

9. RISK RATING
High- review in 2 years

10. NATIONAL STANDARD
Medication Safety– NSQHSS Standard 4

11. REFERENCES
• NSW Health Procedure October 2011 Management of Hypertensive disorders of Pregnancy.
• Sibai, B. M 2003 Diagnosis and Management of Gestational Hypertension and Preeclampsia.
• The American College of Obstetricians and Gynaecologists vol. 102, no 1, pp 181-191.
## Therapeutic range: 1.5 – 3.5 mmol/L

## Toxic range: 4.0 – 8.0 mmol/L

### Toxicity may lead to:
- Suppression of tendon reflexes
- Respiratory depression
- Neuromuscular paralysis
- Cardiac arrest

Date and time Loading Dose given: ___________________________________________________

Time Infusion Commenced: ____________________________  B = Blood to be taken for Mg level

<table>
<thead>
<tr>
<th>HOUR</th>
<th>TIME</th>
<th>INFUSION RATE</th>
<th>URINE OUTPUT</th>
<th>BP Hourly</th>
<th>RESP RATE Hourly</th>
<th>PULSE Hourly</th>
<th>TEMP 4 Hourly</th>
<th>REFLEXES</th>
<th>Comments /Mg LEVEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
MAGNESIUM SULPHATE INFUSION CHART continued

<table>
<thead>
<tr>
<th>HOUR</th>
<th>TIME</th>
<th>INFUSION RATE</th>
<th>URINE OUTPUT</th>
<th>BP Hourly</th>
<th>RESP RATE Hourly</th>
<th>PULSE Hourly</th>
<th>TEMP 4 Hourly</th>
<th>REFLEXES</th>
<th>Comments /Mg LEVEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td><strong>B</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td><strong>B</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td><strong>B</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>